Hazel Szeto, SS-31 peptide, the World's First FDA-Approved Mitochondria-targeted Drug (Longevity Summit, 2025)

It’s a new and improved cardiolipin stabilizer, not just modified SS-31 but a new molecule with enhanced penetration into the central nervous system and improved bioavailability overall (maybe even orally bioavailable). Sounds like it has great potential if it lives up to the expectations!

2 Likes